Background: Semi-mechanistic PKPD models [1] have been previously used to describe the time-course of granulopoiesis and resulting neutropenia from cytotoxic cancer chemotherapy. The B cycle of Hyper-CVAD comprises of intravenously administered high-dose methotrexate (MTX) followed by short sequential infusions of cytarabine for treatment of aggressive non-Hodgkin lymphoma (NHL) for up to four cycles [2]. Neutropenia […]
Geeta Sandhu
- University of Queensland
Author Archive | Geeta Sandhu
Can literature models describe the neutropenic time course produced by hyper-CVAD chemotherapy in non-Hodgkin lymphoma?
February 4, 2013
Authors Geeta Sandhu (1,2), Sally Mapp (1), Christine Carrington (1), Stefanie Hennig (2)
Affiliations 1. Princess Alexandra Hospital 2. The University of Queensland
Presentation type Oral
Presenters Geeta Sandhu
Background: Cytotoxic anticancer drugs methotrexate and cytarabine are incorporated into various high-dose multi-agent chemotherapy regimens (e.g. hyper-CVAD) for aggressive non-Hodgkin lymphoma (NHL). Methotrexate and cytarabine have narrow therapeutic windows and display large inter-patient variability on pharmacokinetic (PK) parameters thus creating difficulty in standardising doses within a population. Studies have shown that neutropenic events after chemotherapy […]